Associated Genetic Biomarkers
INPPL1 is altered in 3.41% of all cancers with endometrial endometrioid adenocarcinoma, breast invasive ductal carcinoma, colon adenocarcinoma, lung adenocarcinoma, and invasive breast carcinoma having the greatest prevalence of alterations .
The most common alterations in INPPL1 are INPPL1 Mutation (1.72%), INPPL1 Amplification (0.70%), INPPL1 Loss (0.17%), INPPL1 R70H (0.04%), and INPPL1 R691Q (0.02%) .
INPPL1 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains INPPL1 status as an inclusion criterion, 1 is phase 1 (1 open).
Trials with INPPL1 status in the inclusion eligibility criteria most commonly target malignant solid tumor .
The most frequent alteration to serve as an inclusion eligibility criterion is INPPL1 Mutation .
Paxalisib and radiation therapy are the most frequent therapies in trials with INPPL1 as an inclusion criteria .
Significance of INPPL1 in Diseases
Malignant Solid Tumor +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.